Refanezumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | myelin-associated glycoprotein |
| Clinical data | |
| Other names | GSK249320 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6608H10156N1732O2064S44 |
| Molar mass | 148298.64 g·mol−1 |
Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.
This drug was developed by GlaxoSmithKline.